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Background: Interleukin (IL)15 is a novel cytokine that
induces T cell proliferation, B cell maturation, natural killer
cell cytotoxicity, and may have a pivotal role in the patho-
genesis of inflammatory disease, acting upstream from
tumour necrosis factor α (TNFα) . Kawasaki disease (KD) is
an inflammatory disease, in which serum levels of
inflammatory cytokines such as TNFα and IL6 are
increased.
Objective: To examine the serum levels of IL15 in KD and
to evaluate the role of IL15 in estimating the severity of
inflammation in KD.
Results and conclusion: There was a significant increase
in the mean (SD) serum levels of IL15 measured in the
acute stage of KD (11.5 (5.8) pg/ml) compared with those
in the subacute stage (1.3 (0.9) pg/ml) (p<0.01) and nor-
mal controls (0.9 (1.0) pg/ml) (p<0.01). The increase in
IL15 correlated with the increase in TNFα (rs=0.66,
p<0.01); however it did not correlate with the levels of
erythrocyte sedimentation rate and C reactive protein, sug-
gesting that IL15 may not be a useful marker in estimating
the severity of inflammation in KD.
Since Kawasaki disease (KD) was first reported in Japanby Dr Kawasaki,1 the clinical manifestations and naturalhistory of KD have been studied extensively. However, its
aetiology and pathophysiology still remain unclear. With
medical progress and the development of antibiotics, im-
proved living standards, and education on hygiene, the
incidence of rheumatic heart disease has been reduced
remarkably, and KD is beginning to be recognised as a major
cause of acquired heart disease these days. KD can be consid-
ered an inflammatory disease because there are changes in T
and B cell levels in patients with the disease, and an increase
in inflammatory cytokines, such as tumour necrosis factor α
(TNFα ) and interleukin (IL) 6.
IL15 is a novel cytokine of 14–15 kDa that is found in acti-
vated monocytes, fibroblasts, normal muscle cells, and human
epidermal keratinocytes.2–4 IL15 has similar features to those
of IL2,5 and requires the β, γ chain of IL2 receptor (IL2R) for its
combination and signal transduction.6 IL15 is especially
involved in natural killer cell cytotoxicity, increasing the
secretion of cytokines from natural killer cells such as
interferon γ, granulocyte macrophage colony stimulating fac-
tor, and TNFα,7–9 and thus acting as one of the proinflamma-
tory cytokines.
Clinically, an increase in IL15 levels was reported in several
inflammatory diseases such as rheumatoid arthritis10 and sys-
temic lupus erythematosus.11 This strongly suggests that IL15
may by related to KD also. In this study we measured the lev-
els of IL15 during the acute and subacute phases of KD. We
also aimed to show whether IL15 might be useful in assessing
the degree of inflammation in KD by comparing and analysing
other inflammatory indicators and IL15 levels.
SUBJECTS AND METHODS
Subjects
Forty serum samples were obtained from 20 patients (12
male) both in the acute (0–2 weeks) and subacute stages (2–4
weeks) of KD. These patients were all admitted to the
Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea. All patients fulfilled at least five of the six crite-
ria for the diagnosis of KD. Atypical KD was excluded in this
study. The control sera were obtained from 10 age matched
children (six male) who were having routine blood samples
taken before elective surgical procedures. The mean (SD) age
of patients and control groups was 2.1 (0.7) years and 2.7 (0.9)
years, respectively. There was no difference in the age and sex
ratio between the patients and the control groups. Informed
consent was obtained from the parents of the children
included in the study.
IL15 and TNFα levels by enzyme linked immunosorbent
assay (ELISA)
Serum was stored at –70°C until measured for levels of IL15
and TNFα by an ELISA kit (Endogen, Woburn, MA, USA).
ELISA was performed according to the manufacturer’s
manual.
Measurement of erythrocyte sedimentation rate (ESR)
and C reactive protein (CRP)
CRP was measured by TDx equipment (Abbott Inc, North
Chicago, IL, USA). ESR was measured by the Westergren
method.
Statistical analysis
A paired t test was used to compare the paired levels of IL15
and TNFα in the acute and subacute phase serum samples.
TheWilcoxon signed rank test was used to compare the values
of the IL15 levels in the acute phase of KD groups and control
groups. The correlation between IL15 level and TNFα , ESR,
and CRP was measured by the Spearman’s rank correlation
test. A value of p<0.05 was regarded as significant.
RESULTS
The mean (SD) IL15 level was 11.5 (5.8) pg/ml in the acute
phase, higher than in the subacute phase (1.3 (0.9) pg/ml)
(p<0.01). The serum IL15 level of control groups was 0.9 (1.0)
pg/ml, lower than in the acute phase (p<0.01); however there
was no significant difference between controls and the
subacute phase of disease (fig 1). The mean (SD) TNFα level
was 24.1 (9.4) pg/ml in the acute phase, higher than in the
subacute phase (11.8 (5.8) pg/ml) and in controls (10.4 (4.9)
pg/ml) (p<0.01).
The serum IL15 level correlated with the TNFα level, which
means that IL15 level was high in patients whose TNFα level
was high (p<0.01, rs=0.66) (fig 2). On the other hand, the
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serum IL15 level in the acute phase did not correlate with the
CRP level and the ESR level (p>0.05) (data not shown).
DISCUSSION
The clinical manifestations of KD have been studied exten-
sively; however, its aetiology and pathophysiology remain
unclear. Various cytokines such as IL1, TNFα, interferon γ, IL6,
and IL10 have been reported to increase during the acute
phase of KD.12–14 TNFα has a central role in the pathogenesis of
vasculitis in KD.15 The TNFα 308 A/G genotype was overrepre-
sented among white subjects with KD who had coronary
artery abnormalities compared with those with normal
echocardiograms.16
IL15, a proinflammatory cytokine, activates TNFα , thereby
inducing inflammation. It has been reported that IL15 levels
increase in some inflammatory diseases. In inflammatory
bowel diseases IL15 levels increase as the disease progresses,
and decrease when the disease improves.12 In rheumatoid
arthritis, IL15 in synovium activates T cells and worsens
inflammatory reactions by inducing TNFα.13 In recent studies,
it has been reported that IL15 levels increase in patients with
systemic lupus erythematosus, showing the role of IL15 in
inflammatory diseases.11
These findings strongly suggest that IL15 levels may
increase in KD also. In this study, we tried to observe changes
in the levels of the inflammatory precursor IL15, and to find
out how effective IL15 might be in assessing the degree of
inflammatory reaction in KD.
Upon comparing IL15 levels in the acute phase, subacute
phase, and controls, we found that IL15 levels were higher in
the acute phase than in the subacute phase and controls. Con-
sidering the immunological changes in KD, we suggest that T
cell activation and B cell proliferation are related to the
increase in IL15.
An increase in the inflammatory precursor IL15 would lead
to an increase in other factors involved in inflammation, espe-
cially TNFα . So, we compared TNFα levels with IL15 levels
and found that IL15 levels were related to TNFα levels. As IL15
levels increased, so did TNFα levels. According to our results,
the inflammatory precursor IL15 increases in the acute phase
of KD, which induces TNFα proliferation and leads to an
inflammatory reaction.
Besides TNFα , other inflammatory indicators such as CRP
and ESR were measured in order to determine whether IL15
might be used as an effective indicator for assessing the degree
of inflammation in KD.
Contrary to our expectations, there was no correlation
between IL15 and either CRP or ESR. The acute phase
reactants were affected by TNFα , IL6, or other various inflam-
matory cytokines. IL6 was especially more closely related to
the acute phase reactants.16 For this reason, it was thought
that the IL15 level did not correlate with both indicators.
Because coronary artery disease is an important inflamma-
tory reaction in KD, the clinical and immunological role of
IL15 in coronary artery disease must be researched. Among
the 20 subjects of our study, however, only one patient had
coronary artery disease. Therefore it was impossible to deter-
mine the correlation between IL15 levels and coronary artery
disease.
With a larger number of patients, we should define the
pathological role of IL15 in KD by comparing IL15 levels in
patients with and without cardiovascular complications. Also
the source of the increased serum IL15 levels must be found
and the role of IL15 in KD elucidated.
CONCLUSION
Serum IL15, which induces inflammation in KD, increases in
the acute phase and decreases in the subacute phase. We
found a correlation between IL15 and TNFα levels. However,
there was no significant correlation between IL15 levels and
the acute phase reactants CRP and ESR. Thus, IL15 cannot be
an effective indicator in assessing the degree of inflammation
in KD.
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